uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QURE uniQure NV

Pre-Mkt 01-21 04:23:16 EST

22.40

-0.44

-1.93%

盘前22.64

+0.24+1.07%

04:19 EST

High22.54	Low21.80	Vol1.32M
Open22.45	D1 Closing22.84	Amplitude3.24%
Mkt Cap1.40B	Tradable Cap910.25M	Total Shares62.29M
T/O29.23M	T/O Rate3.24%	Tradable Shares40.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QURE","market":"US","secType":"STK","nameCN":"uniQure NV","latestPrice":22.4,"timestamp":1768942800000,"preClose":22.84,"halted":0,"volume":1315920,"hourTrading":{"tag":"盘前","latestPrice":22.64,"preClose":22.4,"latestTime":"04:19 EST","volume":236,"amount":5341.0399,"timestamp":1768987176266,"change":0.24,"changeRate":0.010714,"amplitude":0.000446},"delay":0,"changeRate":-0.019264448336252245,"floatShares":40636300,"shares":62291663,"eps":-4.344329,"marketStatus":"Pre-Mkt","change":-0.44,"latestTime":"01-21 04:23:16 EST","open":22.45,"high":22.54,"low":21.8,"amount":29226780.588,"amplitude":0.032399,"askPrice":22.64,"askSize":123,"bidPrice":21.51,"bidSize":159,"shortable":3,"etf":0,"ttmEps":-4.344329,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769005800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1391576400000,"exchange":"NASDAQ","adjPreClose":22.4,"preHourTrading":{"tag":"盘前","latestPrice":22.64,"preClose":22.4,"latestTime":"04:19 EST","volume":236,"amount":5341.0399,"timestamp":1768987176266,"change":0.24,"changeRate":0.010714,"amplitude":0.000446},"postHourTrading":{"tag":"盘后","latestPrice":22.31,"preClose":22.4,"latestTime":"18:28 EST","volume":6678,"amount":149529.4419,"timestamp":1768951703456,"change":-0.09,"changeRate":-0.004018,"amplitude":0.023214},"volumeRatio":0.6633820872046289,"impliedVol":0.8388,"impliedVolPercentile":0.404},"requestUrl":"/m/hq/s/QURE","defaultTab":"news","newsList":[{"id":"2603642687","title":"uniQure NV Director Robert Gut Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603642687","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603642687?lang=en_us&edition=fundamental","pubTime":"2026-01-15 05:27","pubTimestamp":1768426024,"startTime":"0","endTime":"0","summary":"Robert Gut, Director, reported a disposal of common shares of uniQure NV. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. uniQure NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 14, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL5xc3RZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"uniQure NV Director Robert Gut Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0320765992.SGD","BK4139","QURE","LU0109394709.USD"],"gpt_icon":0},{"id":"2603168448","title":"uniQure Showcases Gene Therapy Leadership and Pipeline Progress in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2603168448","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603168448?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:15","pubTimestamp":1768310115,"startTime":"0","endTime":"0","summary":"uniQure NV has released a corporate presentation highlighting its advancements in gene therapy and providing updates on its clinical pipeline. The company reports robust progress, including upcoming data readouts for mesial temporal lobe epilepsy  and Fabry disease within the next three to six months. uniQure’s lead candidate, AMT-130, is positioned as a potential first disease-modifying therapy for Huntington’s disease. The presentation also notes ongoing engagement with the FDA regarding the pathway to Biologics License Application  submission, and outlines the company’s strong financial position with approximately $694.2 million in cash, cash equivalents, and investment securities as of September 30, 2025. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL3g4zwJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","LU0109394709.USD","BK4139","LU0889565916.HKD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2603452610","title":"uniQure NV Director Jack Kaye Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603452610","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603452610?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:22","pubTimestamp":1768252927,"startTime":"0","endTime":"0","summary":"Jack Kaye, Director at uniQure NV, has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. uniQure NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL3h41SY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"uniQure NV Director Jack Kaye Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","QURE","BK4139","LU0109394709.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2602505305","title":"uniQure Stock Jumps After Scheduling FDA Type A Meeting For AMT‑130 Approval Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2602505305","media":"Benzinga","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602505305?lang=en_us&edition=fundamental","pubTime":"2026-01-10 02:14","pubTimestamp":1767982440,"startTime":"0","endTime":"0","summary":"uniQure N.V. (NASDAQ:QURE) shares are popping on Friday after the company said the FDA will review the data package for AMT‑130, its gene therapy for Huntington's disease, with a Type A meeting now scheduled.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/09/Health-care--Lab.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/09/Health-care--Lab.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49820753/uniqure-stock-jumps-after-scheduling-fda-type-a-meeting-for-amt%e2%80%91130-approval-pathway","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49820753/uniqure-stock-jumps-after-scheduling-fda-type-a-meeting-for-amt%e2%80%91130-approval-pathway","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4084","LU0320765992.SGD","BK4219","BK4581","BK4534","AMT","BK4554","LU0889565916.HKD","QURE","BK4139","BK4585","LU0109394709.USD","BK4588"],"gpt_icon":0},{"id":"2602581376","title":"US-Listed Shares of Uniqure Rise 13% Premarket as FDA Review Talks Revive Hopes for Huntington's Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2602581376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602581376?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:08","pubTimestamp":1767964091,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3YA02L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QURE","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2602375913","title":"BUZZ-UniQure rises as US FDA review talks revive hopes for Huntington's therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2602375913","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602375913?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:51","pubTimestamp":1767963066,"startTime":"0","endTime":"0","summary":"BUZZ-UniQure rises as US FDA review talks revive hopes for Huntington's therapy** U.S.-listed shares of Dutch firm UniQure UQ1.F, QURE.O rise 16% to $26.90 premarket** Co says it has scheduled Type A meeting with U.S. FDA to discuss data for potential marketing application for AMT-130** Co seeks accelerated approval for AMT-130, a gene therapy for Huntington's disease, which is a type of brain disorder with no approved treatments** In September, trial data showed AMT130 slowed disease progression by 75%, sending QURE shares soaring more than threefold** However, in November, health regulator said trial data may be inadequate to support marketing application, prompting shares to plunge** UniQure climbed 32% in 2025   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nL4N3YA0W0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","BK4139","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2602736983","title":"uniQure announces Type A meeting scheduled with FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2602736983","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602736983?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:13","pubTimestamp":1767960789,"startTime":"0","endTime":"0","summary":"uniQure (QURE) announced a Type A meeting with the U.S. Food and Drug Administration has been scheduled to discuss the Biologics License Applicatio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-announces-type-a-meeting-scheduled-with-fda-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-announces-type-a-meeting-scheduled-with-fda-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QURE","BK4139","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2592924426","title":"Does uniQure (QURE) FDA Feedback on AMT-130 Reframe Its Risk, Funding and Strategy Profile?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592924426","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592924426?lang=en_us&edition=fundamental","pubTime":"2025-12-18 09:34","pubTimestamp":1766021682,"startTime":"0","endTime":"0","summary":"In early December 2025, uniQure reported that final FDA meeting minutes indicated Phase I/II data for its Huntington's gene therapy AMT-130 are currently unlikely to provide the primary evidence needed for a Biologics License Application, prompting the company to seek a follow-up meeting in early 2026.\nThis feedback raises questions about trial design, endpoint robustness, and the potential need for additional studies, sharpening focus on uniQure’s regulatory pathway and funding capacity for...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/does-uniqure-qure-fda-feedback-on-amt-130-reframe-its-risk-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/does-uniqure-qure-fda-feedback-on-amt-130-reframe-its-risk-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QURE","BK4219","LU0109394709.USD","BK4585","BK4139","AMT","BK4534","BK4084","BK4581","LU0889565916.HKD","BK4588","BK4554","LU0320765992.SGD"],"gpt_icon":0},{"id":"2592932207","title":"uniQure call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2592932207","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592932207?lang=en_us&edition=fundamental","pubTime":"2025-12-17 04:05","pubTimestamp":1765915512,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in uniQure (QURE) with 4,979 calls trading, 1.1x expected, and implied vol increasing almost 4 points to 84.35%. Jan-2...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","BK4139","QURE","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2592939206","title":"What's Going On With uniQure Stock On Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592939206","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592939206?lang=en_us&edition=fundamental","pubTime":"2025-12-17 01:17","pubTimestamp":1765905420,"startTime":"0","endTime":"0","summary":"uniQure shares slid nearly 31% in a month as the FDA raised concerns over whether AMT-130 Phase 1/2 data can support approval.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/16/Indecision-In-The-Stock-Or-Crypto-Market.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/16/Indecision-In-The-Stock-Or-Crypto-Market.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/biotech/25/12/49428299/whats-going-on-with-uniqure-stock-on-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/biotech/25/12/49428299/whats-going-on-with-uniqure-stock-on-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU0320765992.SGD","QURE","LU0109394709.USD","LU0889565916.HKD","BK4139"],"gpt_icon":0},{"id":"2589831064","title":"uniQure Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2589831064","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589831064?lang=en_us&edition=fundamental","pubTime":"2025-12-05 02:52","pubTimestamp":1764874320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QURE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 04, 2025 13:52 ET (18:52 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4139"],"gpt_icon":0},{"id":"2589831281","title":"Why uniQure Stock Is Trading Lower After FDA Meeting Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2589831281","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589831281?lang=en_us&edition=fundamental","pubTime":"2025-12-05 02:30","pubTimestamp":1764873000,"startTime":"0","endTime":"0","summary":"The gene therapy company received final meeting minutes from the FDA regarding a pre-Biologics License Application for AMT-130","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/04/Health-care--Lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/04/Health-care--Lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49216662/why-uniqure-stock-is-trading-lower-after-fda-meeting-update","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49216662/why-uniqure-stock-is-trading-lower-after-fda-meeting-update","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0820561818.USD","QURE","LU0109394709.USD","LU1674673428.USD","IE00B1XK9C88.USD","LU1989772923.USD","LU1162221912.USD","HD","LU1069344957.HKD","BK4581","LU2756315664.SGD","LU0823434740.USD","LU2461242641.AUD","LU1674673691.USD","LU0689472784.USD","LU0889565916.HKD","LU1093756325.SGD","BK4504","LU0354030438.USD","LU1551013425.SGD","LU0238689110.USD","BK4567","LU0942090050.USD","BK4534","LU0354030511.USD","LU1551013342.USD","LU0820562030.AUD","LU1236620750.USD","LU0320765646.SGD","LU1914381329.SGD","LU0823434583.USD","BK4139","BK4533","LU2756315318.SGD","BK4083","IE00BWXC8680.SGD","LU1496350171.SGD","LU1778281490.HKD","LU2361044949.HKD","LU2361044865.SGD","LU1035775433.USD","LU1989772840.SGD","IE00BKVL7J92.USD","LU0234572021.USD","LU0868494708.USD","IE00BSNM7G36.USD","BK4550","LU0079474960.USD","LU0820561909.HKD","LU1093756168.USD"],"gpt_icon":0},{"id":"2588887251","title":"UniQure Shares Drop After More Negative News From FDA on Huntington's Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2588887251","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588887251?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:02","pubTimestamp":1764856920,"startTime":"0","endTime":"0","summary":"UniQure shares fell Thursday after the gene therapy company said its Huntington's disease drug hit more regulatory roadblocks.Shares of the Lexington, Mass., company fell 15% early Thursday, to $21.25, though the stock is up 44% year-to-date.UniQure said the U.S. Food and Drug Administration said data submitted from the Phase I and Phase II studies of its drug AMT-130 are unlikely to provide the primary evidence to support a biologics license application submission. A BLA is a formal request to introduce a biologic product and the FDA reviews it to determine safety and performance before full authorization.UniQure said it's carefully evaluating the feedback and will urgently request a follow-up meeting with the FDA for the first quarter of 2026.\"We are committed to collaborating with the FDA to advance AMT-130 to patients and their families as rapidly as possible,\" said Chief Executive Matt Kapusta.AMT-130 is being developed to slow the progression of Huntington's disease. The FDA prev","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"UniQure Shares Drop After More Negative News From FDA on Huntington's Disease Drug","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","QURE","BK4139","LU0889565916.HKD"],"gpt_icon":0},{"id":"2588881202","title":"uniQure Seeks US FDA Follow-Up Meeting After Being Told Data Do Not Support BLA Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2588881202","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588881202?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:40","pubTimestamp":1764852023,"startTime":"0","endTime":"0","summary":"uniQure  said Thursday that it will \"urgently\" seek a follow-up\" meeting with the US Food and Drug Administration after the regulator said phase 1/2  studies of AMT-130 data are now unlikely to support a Biologics License Application submission.AMT-130 is an investigational gene therapy intended to treat patients with Huntington's disease, the company said.uniQure said it is evaluating the feedback and is looking to meet with the FDA in Q1.Shares of uniQure were down 19% in recent Thursday premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU0109394709.USD","QURE","LU0889565916.HKD","LU0320765992.SGD"],"gpt_icon":1},{"id":"2586267979","title":"uniQure put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2586267979","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586267979?lang=en_us&edition=fundamental","pubTime":"2025-11-27 04:15","pubTimestamp":1764188114,"startTime":"0","endTime":"0","summary":"Bearish flow noted in uniQure (QURE) with 6,020 puts trading, or 2x expected. Most active are Dec-25 20 puts and Dec-25 15 puts, with total volume ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-put-volume-heavy-and-directionally-bearish-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-put-volume-heavy-and-directionally-bearish-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","QURE","BK4139","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2585167595","title":"Biotech Reawakens: Policy Clarity, Breakthrough Data and a Surge in M&A","url":"https://stock-news.laohu8.com/highlight/detail?id=2585167595","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585167595?lang=en_us&edition=fundamental","pubTime":"2025-11-21 10:52","pubTimestamp":1763693545,"startTime":"0","endTime":"0","summary":"Sentiment toward pharmaceuticals—both emerging biotech and large-cap pharma—has shifted meaningfully since we last wrote at the end of FY25. Concerns around US tariff risk and “Most Favoured Nation”  pricing dominated headlines in April, but these issues have since been largely neutralised. As policy uncertainty has cleared, investors have returned their focus to fundamentals.From 30 June to 31 October 2025, the S&P Biotech Index rose more than 30%. Over the same period, HB Biotechnology portfolios delivered a 63% return, driven by multiple outstanding clinical readouts and two strategic takeovers of portfolio companies.Despite this global strength, the ASX healthcare sector has lagged , led by the ongoing weakness in ASX: CSL—once again underscoring the need for a global, diversified approach to healthcare investing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/biotech-reawakens-policy-clarity-breakthrough-data-and-a-surge-in-m-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/biotech-reawakens-policy-clarity-breakthrough-data-and-a-surge-in-m-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["QID","BK7067","CELC","LU0985320562.USD","LU1929549753.HKD","IE00B19Z3B42.SGD","NVIW.SI","NVS","LU2324357040.USD","MRK","BK4559","PSQ","RNA","QLD","VRNA","LU0265550946.USD","VIGL","LU1934455277.USD","IE00BSNM7G36.USD","LU1934455194.USD","USAW.SI","LU0098860793.USD","LU0861579265.USD","REPL","SG9999014559.SGD","USJW.SI","LU0265550359.USD","IE00BN8TJ469.HKD","BK4532","LU0289739699.SGD","LU2023250504.SGD","MNQmain","LU2089984988.USD","IE000M9KFDE8.USD","LU1116320901.HKD","BK4505","LU1430594728.SGD","SGXZ57979304.SGD","TSYW.SI","SQQQ",".IXIC","LU1057294990.SGD","QURE","LU1037948897.HKD","TQQQ","LU0238689110.USD","NQmain","CSL.AU","PFE"],"gpt_icon":1},{"id":"2584896174","title":"Do Rising Losses at uniQure (QURE) Reflect Strategic Investment or Escalating Cost Pressure?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584896174","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584896174?lang=en_us&edition=fundamental","pubTime":"2025-11-19 03:28","pubTimestamp":1763494114,"startTime":"0","endTime":"0","summary":"uniQure N.V. reported its third quarter 2025 financial results on November 10, with revenue rising to US$3.7 million from US$2.29 million a year earlier, accompanied by a net loss of US$80.53 million.\nAn interesting insight from the announcement is that, despite higher quarterly revenue, the company’s losses deepened compared to the previous year, pointing to ongoing cost pressures or investment needs.\nWe’ll now explore how uniQure’s widening quarterly losses and revenue changes could impact...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/do-rising-losses-at-uniqure-qure-reflect-strategic-investmen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/do-rising-losses-at-uniqure-qure-reflect-strategic-investmen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QURE","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","BK4139"],"gpt_icon":0},{"id":"2583582821","title":"A Deep Dive into uniQure (QURE) Valuation After FDA Uncertainty Shakes Huntington’s Disease Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2583582821","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583582821?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:28","pubTimestamp":1762982911,"startTime":"0","endTime":"0","summary":"uniQure (NasdaqGS:QURE) shares experienced a sharp reaction after the FDA unexpectedly indicated that Phase I/II data for AMT-130 in Huntington’s disease may not support the company’s Biologics License Application. This change introduces new regulatory uncertainty for investors.\nSee our latest analysis for uniQure.\nThis regulatory curveball comes after a volatile year for uniQure. Enthusiasm from promising clinical trial results quickly turned to caution as investors reassessed the timeline...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-deep-dive-into-uniqure-qure-valuation-after-fda-uncertaint","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-deep-dive-into-uniqure-qure-valuation-after-fda-uncertaint","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QURE","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","BK4139"],"gpt_icon":0},{"id":"1138163270","title":"Stock Track | uniQure NV Soars 5.71% Pre-market on Bullish Analyst Ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=1138163270","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138163270?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:03","pubTimestamp":1762952608,"startTime":"0","endTime":"0","summary":"uniQure NV (QURE) shares are surging 5.71% in pre-market trading on Wednesday, building on the previous day's gains. The biotechnology company's stock is attracting investor attention following...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["QURE"],"gpt_icon":0},{"id":"2582375192","title":"uniQure (QURE) Gets a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375192","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375192?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:19","pubTimestamp":1762949968,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Yanan Zhu maintained a Buy rating on uniQure today and set a price target of $60.00. Zhu covers the Healthcare sector, focusing...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/uniqure-qure-gets-a-buy-from-wells-fargo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/uniqure-qure-gets-a-buy-from-wells-fargo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0052756011.USD","LU0267386448.USD","LU1280957306.USD","LU0742534661.SGD","IE000M9KFDE8.USD","XBI","LU2236285917.USD","LU0314106906.USD","IE00B7SZLL34.SGD","LU0320765489.SGD","LU0787776722.HKD","LU0251131958.USD","LU1267930573.SGD","LU1791807156.HKD","LABU","LU2361045086.USD","LU0256863811.USD","LU1074936037.SGD","LU1267930227.SGD","LU1814569148.SGD","BK4504","LU0310799852.SGD","IE0002270589.USD","LU0175139822.USD","LU0310800379.SGD","LU0889565916.HKD","XLV","BK4559","QURE","LU1267930490.SGD","LU0683600562.USD","LU0211327993.USD","LU0648001328.SGD","LU1069347547.HKD","BK4585","LU2461242641.AUD","LU0128525689.USD","LU0310800965.SGD","LU0640476718.USD","LU0128525929.USD","LU0477156953.USD","LU1506573853.SGD","LU0868494708.USD","LU1363072403.SGD","LU0048573561.USD","LU1035773651.USD","BK4139","LU0106831901.USD","LU0251142724.SGD","BK4207"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.uniqure.com","stockEarnings":[{"period":"1week","weight":0.0419},{"period":"1month","weight":-0.0663},{"period":"3month","weight":-0.6261},{"period":"6month","weight":0.4727},{"period":"1year","weight":0.5943},{"period":"ytd","weight":-0.0639}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.01015},{"month":2,"riseRate":0.545455,"avgChangeRate":0.064233},{"month":3,"riseRate":0.25,"avgChangeRate":-0.054124},{"month":4,"riseRate":0.416667,"avgChangeRate":0.018299},{"month":5,"riseRate":0.666667,"avgChangeRate":0.042965},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.009437},{"month":7,"riseRate":0.25,"avgChangeRate":0.033059},{"month":8,"riseRate":0.5,"avgChangeRate":0.005984},{"month":9,"riseRate":0.25,"avgChangeRate":0.122705},{"month":10,"riseRate":0.5,"avgChangeRate":0.060394},{"month":11,"riseRate":0.75,"avgChangeRate":0.0616},{"month":12,"riseRate":0.25,"avgChangeRate":0.125134}],"exchange":"NASDAQ","name":"uniQure NV","nameEN":"uniQure NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"uniQure NV,QURE,uniQure NV股票,uniQure NV股票老虎,uniQure NV股票老虎国际,uniQure NV行情,uniQure NV股票行情,uniQure NV股价,uniQure NV股市,uniQure NV股票价格,uniQure NV股票交易,uniQure NV股票购买,uniQure NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}